NKNural Kiper

Nural Kiper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nural Kiper has a total of 311 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Flexible bronchoscopy in pediatric atelectasis: bronchoscopic findings, management changes, and factors associated with radiographic resolution

    by Ömer Faruk İpEk, Ebru Yalçın, Özge Özen, Birce Sunman, Nagehan Emiralioğlu Ordukaya, Deniz Doğru, Uğur Özçelik, Nural Kiper

    Background. Flexible bronchoscopy (FB) is widely used in children with atelectasis; however, the optimal timing of FB and the influence of underlying disease on radiographic resolution remain uncertain. We aimed to describe bronchoscopic and microbiological findings, subsequent management changes, radiographic outcomes, and factors associated with atelectasis resolution in children who underwent FB. Methods. This retrospective cohort included 108 children (0–18 years) who underwent FB for atelectasis between 2017 and 2022 with chest radiograph-based follow-up. Outcomes were immediate radiographic response and final radiographic status. An exploratory Cox model assessed time to complete resolution and included detection-to-FB interval, macroscopic pathological findings, congenital heart disease, primary ciliary dyskinesia, immunodeficiency, asthma and cystic fibrosis. Results. Median age at FB was 4.9 years (IQR: 2.5–8.8; range: 14 days to 18 years). 67/108 patients (62.0%) had underlying disorders. Macroscopic pathological findings were observed in 95.4%. Bronchoalveolar lavage cultures were positive in 75/105 patients (71.4%) and additional treatment was administered in 67/108 patients (62.0%). At final radiographic status, complete, partial, and no resolution were observed in 44/108 (40.7%), 30/108 (27.8%), and 34/108 patients (31.5%), respectively. In the exploratory Cox model, each 30-day increase in detection-to-FB interval was associated with a lower hazard of complete resolution (HR: 0.88, 95% CI: 0.80–0.98; p=0.018), but this association was attenuated after excluding intervals >365 days (p=0.169). Procedure-related complications occurred in 4/108 patients (3.7%). Conclusions. In selected children undergoing FB for atelectasis, bronchoscopy frequently revealed clinically relevant bronchoscopic and microbiological findings, informed subsequent management, and was followed by partial or complete radiographic resolution in more than two-thirds of patients. Although the timing-related findings should be interpreted cautiously, particularly because the association was attenuated in sensitivity analysis, this study supports the role of FB as a complementary diagnostic and management-guiding tool in pediatric atelectasis.

  • Open Access

    Heart rate response and clinical determinants of Glittre activities of daily living test performance in pediatrics with cystic fibrosis

    by Cemile Bozdemir, Elif Kocaaga, Haluk Tekerlek, Deniz Inal-Ince, Hulya Arikan, Melda Saglam, Naciye Vardar-Yagli, Ebru Calik, Ugur Ozcelik, Deniz Dogru, et al.

    The Pediatric Glittre Activities of Daily Living Test (TGlittre-P) is a field test designed to assess the functional performance of activities of daily living (ADL) in pediatric patients with cystic fibrosis (CF). However, the effects of TGlittre-P on heart rate response and the clinical determinants of test performance in this population remain insufficiently understood. To compare the heart rate response elicited by the TGlittre-P and the six-minute walk test (6MWT), and to identify pulmonary and extrapulmonary factors associated with TGlittre-P performance in pediatric patients with CF. Fifty-four pediatric patients with CF (mean age = 14.46 ± 2.16 years, 31 females and 23 males) were included in this cross-sectional study. ADL performance was assessed using the TGlittre-P, and functional capacity was assessed using the 6MWT. Pulmonary function, including forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC), maximal inspiratory and expiratory pressure (MIP and MEP, respectively), handgrip strength (HGS %) and quadriceps muscle strength (QMS %) were measured. A multiple linear regression analysis model was used to determine independent predictors of TGlittre-P performance. The mean TGlittre-P duration was 2.00 ± 0.53 min. There was agreement between recorded peak heart rate (HRpeak) responses during the TGlittre-P and 6MWT (mean difference: -2.33%, with limits of agreement ranging from − 41.19 to 36.52). HRpeak (bpm), HRpeak (% predicted HRmax), and pre-to-post changes in systolic and diastolic blood pressure (mmHg), oxygen saturation (%), and perceived effort were not different between TGlittre-P and 6MWT (p > 0.05). TGlittre-P duration (min) correlated with 6MWT distance (m), FEV1 (%), FEV1z-score, FVC (%), FVC z-score, MIP (cmH2O), MEP (cmH2O), HGS (%) and QMS (%) (p < 0.05). The FEV1 z-score, height z-score and sex were predictors for TGlittre-P duration (min) [Adjusted R2 = 0.402, F(3, 53) = 11.755, p < 0.001, constant = 1.625]. No significant differences were observed in the measured heart rate response between the TGlittre-P and 6MWT. TGlittre-P performance is strongly associated with pulmonary function and respiratory and peripheral muscle strength. Airway obstruction was the strongest predictor of TGlittre-P performance in this population.

  • Interstitial Lung Disease in Children: Rare Genetic Variants Beyond Surfactant Dysfunction

    by Satı Özkan Tabakçı, Şule Selin Akyan Soydaş, Gökçen Dilşa Tuğcu, Güzin Cinel, Ayşe Ceren Sağdıç, Uğur Özçelik, Sinem Can Oksay, Çiğdem Korkmaz, Fazılcan Zirek, Handan Kekeç, et al.

    Background: Advances in genetic analysis techniques and strategies have enabled the identification of rare novel genetic entities in children's interstitial lung disease (chILD). Aims: To describe an extensive array of demographic, clinical, radiological, and laboratory data from a national registry of children with diffuse lung disease caused by rare and novel genetic variants. Study Design: Retrospective cohort study. Methods: This study used data from the chILD Türkiye (chILD‐TR) registry to analyze rare genetic chILD subtypes, excluding surfactant protein gene variants, ABCA3 , and NKX2‐1 , between November 2021 and January 2024. Of 671 patients in chILD‐TR, 182 underwent genetic analysis excluding surfactant protein‐related variants, resulting in 37 patients identified with rare genetic variants included in the study. Results: Among the 37 patients with rare genetic variants, 19 (51.4%) were male, and the median age at diagnosis was 40.5 months (IQR 15.5–115.5). Genetic analysis conducted on 15 patients identified COPA , STAT3 , STING1 , ADA , ZNFX1 , PIK3CD , PLCG2 , OAS1, CCR2, RNF168 and ATM gene variants, which are associated with immunodeficiency/dysregulation and autoinflammation; 15 NPC1 , SMPD1 , GBA1 , SLC7A7 , MARS1 , FARSB , and PEPD genes, variants linked to inherent metabolic errors. Seven patients were found with TBX4 , SLC34A2 , PLG , and SMAD4 gene variants. All patients were born at term, and five (13.5%) of them were small for gestational age. Two patients (5.4%) had previously been on a mechanical ventilator in the neonatal intensive care unit, 25(67.6%) had familial consanguinity, and 23 (62.1%) had comorbid systemic disease. Thirteen patients (35.1%) required oxygen support. All patients underwent chest computed tomography scans at initial assessment, showing ground‐glass opacities in 29 (78.3%), infiltrations in 27 (72.9%), and interlobular septal thickening in 20 (54%). Eight patients (21.6%) received oral steroids, and six (16.2%) received pulse steroids in addition to their primary treatments for systemic diseases. Conclusions: Interstitial lung disease rarely occurs in children, but increased awareness and genetic testing may enable earlier diagnosis. Recognizing that diffuse parenchymal lung disease can occur in rare systemic diseases may improve diagnoses and treatment.

  • Open Access

    Clinical features associated with Pseudomonas aeruginosa colonization in children under 2 years of age: a retrospective study of Cystic Fibrosis Registry

    by Ece Ocak, Güzin Cinel, Gökçen Dilşa Tuğcu, Sanem Eryılmaz Polat, Dilber Ademhan Tural, Beste Özsezen, Ebru Yalçın, Nural Kiper, Velat Şen, Hadice Selimoğlu Şen, et al.

    Background. Respiratory colonization with Pseudomonas aeruginosa is associated with increased morbidity and mortality in cystic fibrosis (CF) patients. This study aims to assess the clinical characteristics and associated factors of CF infants under two years of age with P. aeruginosa colonization in Türkiye. Method. Of the 1637 patients registered in the Cystic Fibrosis Registry of Türkiye in 2019, 284 patients under two years of age were included in this retrospective cross-sectional study. Patients were classified into two groups: those with P. aeruginosa colonization (Group 1) and those without (Group 2). Cystic fibrosis transmembrane conductance regulator (CFTR) gene functions were categorized according to CFTR mutation functional class. Results. Twenty-three patients (8.1%) were categorized as Group 1 and 262 participants (91.9%) were classified as Group 2. Infants with P. aeruginosa colonization (Group 1) were more likely to have minimal CFTR function compared with those without colonization (87% vs. 39.8%, p = 0.017). In addition, both Staphylococcus aureus colonization (47.8% vs. 7.3%, p < 0.001) and methicillin-resistant S. aureus positivity (17.4% vs. 6.1%, p = 0.042) were observed more commonly in Group 1. There were no statistical differences between the groups in terms of age at diagnosis, gender, mean z-scores of weight and height, newborn screening test positivity, sweat chloride test results, and pancreatic insufficiency (p > 0.05). Univariate logistic regression analysis did not identify significant associated factors for P. aeruginosa colonization. Conclusions. Our findings suggest that minimal CFTR function and S. aureus colonization are associated with P. aeruginosa colonization in CF patients under two years of age. Further studies are needed to investigate associated factors for early P. aeruginosa colonization, eradication treatment effectiveness, and longitudinal outcomes of in CF patients under two years of age.

  • Open Access

    Tuberculosis infection in BCG vaccinated children and adolescents with rheumatological diseases treated by tumor necrosis factor-α inhibitors

    by Dilber Ademhan Tural, Deniz Doğru, Beste Özsezen, Azer Karaman, Birce Sunman, Halime Nayir Büyükşahin, İsMail Güzelkaş, Didem Alboğa, Meltem Akgül Erdal, Nagehan Emiralioğlu Ordukaya, et al.

    Tumor necrosis factor-alpha (TNF-α) inhibitors increase the risk of developing active tuberculosis (TB) disease through reactivation of latent TB infection (LTBI). We aimed to analyze TB infections in BCG-vaccinated children and adolescents with rheumatologic diseases treated with TNF-α inhibitors in a country of moderate risk for TB. This retrospective study included 261 children with a rheumatic disease who were treated with TNF-α inhibitors and followed up on a fixed schedule between January 2018 and December 2022. Demographic and clinical characteristics, as well as TB screening results, were recorded. The mean age of the patients was 14.0 ± 4.1 years; 56.7% were female. The mean age at initiation of TNF-α inhibitors was 11.0 ± 5.1 years, the mean duration of TNF-α inhibitor use was 4.1 ± 2.7 years, and the mean follow-up time was 4.1 ± 2.6 years. During the study period, 75 (29.0%) patients were diagnosed with LTBI: 44% at the initial evaluation and 56% during follow-up. None of them progressed to TB disease. Only two cases of active TB disease were seen without prior documented LTBI. Age and duration of TNF-α inhibitor use were significantly associated with LTBI positivity. Conclusion : TB screening is necessary in children and adolescents at the initiation of and during TNF-α inhibitor therapy. The risk of LTBI positivity increases with age and longer use of TNF-α inhibitors. No cases progressed from LTBI to active TB, which may support the effectiveness of current screening and prophylaxis strategies in our country. What is Known: • TNF-α inhibitors are associated with an increased risk of developing active tuberculosis (TB) disease as a result of the reactivation of latent TB infection (LTBI). What is New: • Screening for LTBI at initiation and during TNF-α inhibitor treatment, along with appropriate LTBI prophylaxis, prevented LTBI reactivation into active TB disease in BCG-vaccinated patients receiving TNF-α inhibitors. • Increasing age and duration of TNF-α inhibitor treatment are associated with the risk of LTBI positivity.

  • Malnutrition in childhood interstitial lung diseases is associated with reduced lung function and greater disease severity: insights from the chILD-EU registry

    by Tugba Ramasli Gursoy, Nagehan Emiralioglu, Matthias Griese, Elias Seidl, Julia Rodler, Nicolaus Schwerk, Julia Carlens, Martin Wetzke, Nadia Nathan, Steve Cunningham, et al.


  • Idiopathic Pulmonary Hemosiderosis in a Child Diagnosed by Transbronchial Cryobiopsy

    by Aslı İmran Yılmaz, Dirk Schramm, Ayşe Şimşek, Sevgi Pekcan, Nural Kiper


  • Open Access

    Immunodeficiency-Associated Childhood Interstitial Lung Diseases: Data from Türkiye chILD Registry

    by Handan Kekeç, Tuğba Şişmanlar Eyüboğlu, Ayşe Tana Aslan, Volkan Medeni, Fazılcan Zirek, Mervenur Tekin, Figen Gülen, İsMail Güzelkaş, Sanem Eryılmaz Polat, Ayça Kıykım, et al.

    Childhood interstitial lung diseases (chILD) and immunodeficiencies are rare, heterogeneous, and clinically challenging disorders. This study aimed to evaluate the clinical and radiological characteristics of immunodeficiency-related chILD using data from the Türkiye chILD Registry (chILD-TR). We conducted a retrospective cohort study using data collected from the chILD-TR in 2023. Patients registered with the B3 code, according to the chILD-European classification, from 18 participating centers were included. Patients were classified into primary immunodeficiency (PID) and secondary immunodeficiency (SID) groups. Demographic, clinical, and radiological variables were compared between the two groups. Among 667 patients registered in the chILD-TR, 114 (17%) had immunodeficiency-related chILD, including 53 (47%) females. The median current age was 156 months (range: 23-357), the age at symptom onset was 60 months (range: 0-215), and the age at chILD diagnosis was 85 months (range: 2-217). PID was identified in 77 patients (67.6%) and SID in 37 patients (32.4%). The PID group had significantly lower median current age, age at first symptom, and age at chILD diagnosis compared with the SID group (p < 0.05). No significant differences were observed in growth z-scores between the groups (p > 0.05). A history of hematopoietic stem cell transplantation (HSCT) and a diagnosis of bronchiolitis obliterans (BO) were more frequent in the SID group (p < 0.05). The most common computed tomography findings were ground-glass opacities in PID and mosaic perfusion in SID. During follow-up, 14 patients (12.3%) died. Immunodeficiency-associated chILD encompasses a heterogeneous spectrum of disorders and is associated with increased mortality. Distinct clinical and radiological patterns were observed between PID and SID. These findings underscore the importance of early detection, individualized diagnostic strategies, and ongoing follow-up to improve outcomes in this high-risk population. Recognition of post-infectious BO and following HSCT is critical for timely intervention.

  • Open Access

    Etiologies of chronic cough in children: a two-year experience from a tertiary pediatric pulmonology center

    by Yasi̇n Maruf Ergen, Nagehan Emi̇rAli̇oĞlu, Ebru Yalçin, Deni̇z Doğru, Uğur Özçeli̇k, Nural Ki̇pEr

    Background/aim: Chronic cough is a common yet diagnostically challenging symptom in pediatric pulmonology. This study aimed to evaluate the etiologies of chronic cough in children referred to a tertiary center and to analyze the relationship between specific cough characteristics and final diagnoses. Materials and methods: This retrospective study evaluated patients presenting with chronic cough (duration >4 weeks) at a tertiary pediatric pulmonology center. Demographic data, cough characteristics (wet vs. dry), and diagnostic findings were analyzed. Results: A total of 62 patients were included. A specific etiology was identified in 95.1% of the patients. Asthma and reactive airway disease were the most common diagnoses (45.2%), predominantly associated with dry cough. Notably, we observed an unexpectedly high prevalence of primary ciliary dyskinesia (PCD) (19.4%) and cystic fibrosis (CF) (6.5%), particularly in the wet cough group. This distribution differs significantly from primary care studies, reflecting the selected, refractory nature of patients referred to our tertiary center. Protracted bacterial bronchitis (PBB) was identified in only 3.2% of cases. Conclusion: While asthma remains the leading cause of dry cough, structural lung diseases such as PCD and CF are major etiologies in children presenting with chronic wet cough in tertiary settings. The high rate of these serious conditions underscores the need for early and detailed investigation in patients unresponsive to standard therapies, rather than repeated empirical treatments for presumed PBB.

  • Open Access

    miRNA-target gene network analysis in siblings with cystic fibrosis and phenotypic variability

    by Ayberk Mustafaoğlu, Senem Noyan, Yeli̇z Z. Akkaya Ulum, Bala Gür Dedeoğlu, Nagehan Emi̇rAli̇oĞlu, Uğur Özçeli̇k, Ebru Yalçin, Deni̇z Doğru, Nural Ki̇pEr, Di̇dEm Dayangaç Erden

    Background/aim: Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CF is characterized by respiratory tract infections, pancreatic insufficiency, meconium ileus, intestinal obstruction, and male infertility. A genotype to phenotype correlation is difficult to establish because of the heterogeneity of disease severity. Even patients with the same CFTR mutation can have varying clinical severities. In recent years, studies have explored the role of microRNA (miRNA) expression in the regulation of respiratory diseases. However, no research has been conducted to date on miRNAs in siblings with the same CFTR mutation. Materials and methods: Nasal cells of CF siblings from two families with discordant phenotype (n = 2 per family) were collected, and differentially expressed miRNAs were identified using miRNA arrays. Differentially expressed miRNAs and their target genes were determined using several bioinformatic databases and tools. Results: miR-449c-5p, miR-92b-3p, miR-34c-3p, miR-34c-5p, miR-6732-5p, and miR-4793-3p were differentially expressed in patients with severe disease compared to mild. CXCL1, CXCL2, DUSP1, GCLC, ICAM1, KIT, PRKAA2, and PTGS2 genes were identified as the target genes of candidate miRNAs (miR-34c-3p, miR-92b-3p, miR-449c-5p, miR-4793-3p). miRNA-mRNA interaction network analysis was performed and strong interaction was shown between miR-449c-5p target genes (CXCL1, CXCL2, PTGS2, ICAM1). CXCL1 expression decreased 5.28-fold in patients with severe disease compared to those with mild (p = 0.01). Conclusion: Our results highlight the importance of miR-449c-5p interaction with CXCL1 and other target genes related to inflammation. Further studies should focus on the functional analysis of miR-449c-5p.